Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 399

1.

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS.

JAMA. 1999 Nov 24;282(20):1921-8.

PMID:
10580457
2.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
3.

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.

Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS.

Mayo Clin Proc. 1999 Nov;74(11):1095-105.

PMID:
10560596
4.

Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.

J Rheumatol. 2000 Aug;27(8):1876-83.

PMID:
10955327
6.
7.

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.

Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.

Am J Gastroenterol. 2001 Apr;96(4):1019-27.

PMID:
11316141
8.

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

JAMA. 1999 Nov 24;282(20):1929-33.

PMID:
10580458
9.

[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].

[No authors listed]

MMW Fortschr Med. 2004 Apr 8;146(15):66. German. No abstract available.

PMID:
15373027
10.

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.

Goldenberg MM.

Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8. Review.

PMID:
10509845
11.
12.

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.

PMID:
12907325
13.

A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.

Moberly JB, Harris SI, Riff DS, Dale JC, Breese T, McLaughlin P, Lawson J, Wan Y, Xu J, Truitt KE.

Dig Dis Sci. 2007 Feb;52(2):442-50. Epub 2007 Jan 10.

PMID:
17216336
14.
15.

Celecoxib for rheumatoid arthritis.

Megeff CE, Strayer SM.

J Fam Pract. 2000 Feb;49(2):108-9. No abstract available.

PMID:
10718683
16.

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.

Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group.

Gut. 2003 Jun;52(6):820-6. Erratum in: Gut. 2003 Dec;52(12):1800.

17.

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

Clemett D, Goa KL.

Drugs. 2000 Apr;59(4):957-80. Review. Erratum in: Drugs 2001;61(4):498.

PMID:
10804043
18.

Celecoxib clinical profile.

Tive L.

Rheumatology (Oxford). 2000 Dec;39 Suppl 2:21-8; discussion 57-9. Review.

PMID:
11276798
20.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246

Supplemental Content

Support Center